Novel Feline Immunodeficiency Virus
- Detailed Technology Description
- None
- *Abstract
-
It is estimated that up to 3% of cats are infected with Feline Immunodeficiency Virus (FIV) which causes a chronic disease similar to AIDS in humans. After initial infection, the virus can remain dormant and reactivate later in life to suppress the cat's immune system. To date there is no treatment for FIV infection. Although a vaccine is currently available, it remains unpopular for two reasons: (i) the adjuvant used is associated with unwanted heath risks; and (ii) vaccinated cats test positive for FIV, making it difficult to discern infected from vaccinated cats.
Potential Applications & Advantages:
- Peptide sequences have been ascribed for use as antigens in FIV vaccine development;
- FIV-OMA is able to grow well in an established cell line to high titers which would be valuable for commercial vaccine production;
- FIV-Oma can be used for the development of a diagnostic for FIV;
- Because FIV in cats is similar to HIV/AIDS in humans, advancement in treating, immunizing, or better detecting FIV will also be informative to AIDS research.
Patents: 6,284,253; 6,579,527
Contact: Phillip Owh, po62@cornell.edu, 607.254.4508
- Country/Region
- USA
For more information, please click Here
